Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashwani Kumar Arora

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Human Vaccines & Immunotherapeutics|January 27, 2015
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenMarkus Knuf, Geert Leroux-Roels, Hans Rümke, et al.
Vaccine|April 29, 2019
Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccinePierre Van Damme, Geert Leroux-Roels, Corinne Vandermeulen, et al.
Human Vaccines & Immunotherapeutics|September 20, 2017
MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in MexicoAurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S Patel, et al.
Frontiers in Microbiology|March 13, 2023
Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary disease: Results from three clinical studies in Europe and North AmericaSonia Schoonbroodt, Jean-Laurent Ichanté, Sophie Boffé, et al.
Travel Medicine and Infectious Disease|May 31, 2014
Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center studyMartin Alberer, Gerd Burchard, Tomas Jelinek, et al.
ERJ Open Research|September 29, 2022
Airway pathogens detected in stable and exacerbated COPD in patients in Asia-PacificLaura Taddei, Lucio Malvisi, David S Hui, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
Vaccine: X|November 25, 2021
Long-term immunogenicity and safety of a non-typeable <i>Haemophilus influenzae</i>-<i>Moraxella catarrhalis</i> vaccine: 4-year follow-up of a phase 1 multicentre trialPhilippe De Smedt, Geert Leroux-Roels, Corinne Vandermeulen, et al.
Drugs in R&D|March 18, 2024
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenesUsman Nakakana, Alimamy Serry-Bangura, Bassey Effiom Edem, et al.
Plos Neglected Tropical Diseases|June 7, 2018
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adultsPhirangkul Kerdpanich, Pornthep Chanthavanich, Mari Rose De Los Reyes, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|January 27, 2015
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenMarkus Knuf, Geert Leroux-Roels, Hans Rümke, et al.
Vaccine|April 29, 2019
Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccinePierre Van Damme, Geert Leroux-Roels, Corinne Vandermeulen, et al.
Human Vaccines & Immunotherapeutics|September 20, 2017
MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in MexicoAurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S Patel, et al.
Frontiers in Microbiology|March 13, 2023
Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary disease: Results from three clinical studies in Europe and North AmericaSonia Schoonbroodt, Jean-Laurent Ichanté, Sophie Boffé, et al.
Travel Medicine and Infectious Disease|May 31, 2014
Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center studyMartin Alberer, Gerd Burchard, Tomas Jelinek, et al.
ERJ Open Research|September 29, 2022
Airway pathogens detected in stable and exacerbated COPD in patients in Asia-PacificLaura Taddei, Lucio Malvisi, David S Hui, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
Vaccine: X|November 25, 2021
Long-term immunogenicity and safety of a non-typeable <i>Haemophilus influenzae</i>-<i>Moraxella catarrhalis</i> vaccine: 4-year follow-up of a phase 1 multicentre trialPhilippe De Smedt, Geert Leroux-Roels, Corinne Vandermeulen, et al.
Drugs in R&D|March 18, 2024
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenesUsman Nakakana, Alimamy Serry-Bangura, Bassey Effiom Edem, et al.
Plos Neglected Tropical Diseases|June 7, 2018
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adultsPhirangkul Kerdpanich, Pornthep Chanthavanich, Mari Rose De Los Reyes, et al.
Pageof 3